Scinai Immunotherapeutics Ltd. (SCNI)
NASDAQ: SCNI · Real-Time Price · USD
0.2910
-0.0305 (-9.49%)
At close: Jun 22, 2026, 4:00 PM EDT
0.3025
+0.0115 (3.95%)
After-hours: Jun 22, 2026, 7:59 PM EDT

Scinai Immunotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
1.211.310.66---
Revenue Growth (YoY)
10.16%99.24%----
Cost of Revenue
-5.21-3.96-1.24---
Gross Profit
-4-2.65-0.58---
Selling, General & Admin
-2.74-2.52-2.53-4.515.37.63
Research & Development
-1.7-2.37-5.53-5.215.773.25
Other Operating Expenses
---0.01--0.01
Total Operating Expenses
-4.44-4.89-8.06-9.7111.0610.86
Operating Income
-1.882.247.489.71-11.06-10.86
Total Non-Operating Income (Expense)
5.86-14.76--5.27-2.66
Pretax Income
3.982.2422.249.71-16.33-13.52
Net Income
3.982.2422.249.71-16.33-13.52
Net Income to Common
-2.072.2422.249.71-16.338.21
Net Income Growth
--89.94%129.11%---
Shares Outstanding (Basic)
321000
Shares Outstanding (Diluted)
321000
Shares Change (YoY)
140.96%189.55%106.41%107.22%33.56%27.37%
EPS (Basic)
-0.743.60-16.0040.00-80.00
EPS (Diluted)
-0.743.60-16.0040.00-80.00
EPS Growth
----60.00%--
Free Cash Flow
-6.46-6.06-6.35-10.02-8.1-7.57
Free Cash Flow Per Share
-2.31-2.59-7.87-25.65-42.97-53.60
Gross Margin
-329.32%-202.29%-88.15%---
Operating Margin
-154.98%170.71%1136.47%---
Profit Margin
327.59%170.71%3379.48%---
FCF Margin
-532.46%-461.86%-964.59%---
EBITDA
-0.363.669.1310.22-10.5-10.39
EBITDA Margin
-29.53%279.10%1387.08%---
EBIT
-1.882.247.489.71-11.06-10.86
EBIT Margin
-154.98%170.71%1136.47%---
SEC Filings: 10-K · 10-Q